Laura C Cappelli1, Mehmet T Dorak2, Maria P Bettinotti3, Clifton O Bingham1, Ami A Shah1. 1. Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. School of Life Sciences, Pharmacy & Chemistry, Kingston University London, London, UK. 3. Immunogenetics Laboratory, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
OBJECTIVE: To evaluate the frequency of HLA class I and II alleles associated with traditional forms of inflammatory arthritis in patients with immune checkpoint inhibitor (ICI)-induced inflammatory arthritis as compared with population controls. METHODS: High-resolution HLA typing was performed on 27 patients with ICI-induced inflammatory arthritis and 726 healthy controls. Genotyping at the shared epitope (SE) locus (HLA DRB1) was performed on 220 RA cases. Allele-positivity rates and frequency of having at least one SE allele were compared using Fisher's exact test between ICI-induced inflammatory arthritis and healthy controls. Frequency of having at least one SE allele was also compared between ICI-induced inflammatory arthritis and RA cases. RESULTS: Twenty-six patients with ICI-induced inflammatory arthritis were of European descent, and one was African American. In those 26 patients, 16 (61.5%) had at least one SE allele, significantly different from healthy controls of European descent, in whom 299 (41.2%) had at least one SE allele (odds ratio 2.3, P = 0.04). The allele-positivity rate of DRB1*04: 05 was also higher in the ICI-induced inflammatory arthritis group. The ICI-induced inflammatory arthritis population and RA patients of European descent did not differ in frequency of having at least one SE allele, but ICI-induced inflammatory arthritis patients were more likely to be autoantibody-negative for RF and anti-CCP antibodies. CONCLUSION: Patients with ICI-induced inflammatory arthritis of European descent were more likely to have at least one SE allele than healthy controls. Further studies are needed to validate these findings and investigate whether a unique immunogenetic framework increases risk for different immune-related adverse events.
OBJECTIVE: To evaluate the frequency of HLA class I and II alleles associated with traditional forms of inflammatory arthritis in patients with immune checkpoint inhibitor (ICI)-induced inflammatory arthritis as compared with population controls. METHODS: High-resolution HLA typing was performed on 27 patients with ICI-induced inflammatory arthritis and 726 healthy controls. Genotyping at the shared epitope (SE) locus (HLA DRB1) was performed on 220 RA cases. Allele-positivity rates and frequency of having at least one SE allele were compared using Fisher's exact test between ICI-induced inflammatory arthritis and healthy controls. Frequency of having at least one SE allele was also compared between ICI-induced inflammatory arthritis and RA cases. RESULTS: Twenty-six patients with ICI-induced inflammatory arthritis were of European descent, and one was African American. In those 26 patients, 16 (61.5%) had at least one SE allele, significantly different from healthy controls of European descent, in whom 299 (41.2%) had at least one SE allele (odds ratio 2.3, P = 0.04). The allele-positivity rate of DRB1*04: 05 was also higher in the ICI-induced inflammatory arthritis group. The ICI-induced inflammatory arthritis population and RA patients of European descent did not differ in frequency of having at least one SE allele, but ICI-induced inflammatory arthritispatients were more likely to be autoantibody-negative for RF and anti-CCP antibodies. CONCLUSION:Patients with ICI-induced inflammatory arthritis of European descent were more likely to have at least one SE allele than healthy controls. Further studies are needed to validate these findings and investigate whether a unique immunogenetic framework increases risk for different immune-related adverse events.
Authors: Laura C Cappelli; Anna Kristina Gutierrez; Alan N Baer; Jemima Albayda; Rebecca L Manno; Uzma Haque; Evan J Lipson; Karen B Bleich; Ami A Shah; Jarushka Naidoo; Julie R Brahmer; Dung Le; Clifton O Bingham Journal: Ann Rheum Dis Date: 2016-06-15 Impact factor: 19.103
Authors: Laura C Cappelli; Julie R Brahmer; Patrick M Forde; Dung T Le; Evan J Lipson; Jarushka Naidoo; Lei Zheng; Clifton O Bingham; Ami A Shah Journal: Semin Arthritis Rheum Date: 2018-03-22 Impact factor: 5.532
Authors: Ana M Santos; Paola Peña; Mabel Avila; Ignacio Briceño; Carlos Jaramillo; Gilberto Vargas-Alarcon; Juan C Rueda; Eugenia-Lucia Saldarriaga; Jose-Ignacio Angarita; Nancy Martinez-Rodriguez; John Londono Journal: Clin Rheumatol Date: 2016-12-24 Impact factor: 2.980
Authors: Robert Winchester; Jon Giles; Deepak Jadon; Muhammed Haroon; Neil McHugh; Oliver FitzGerald Journal: Clin Immunol Date: 2016-07-25 Impact factor: 3.969
Authors: Diane van der Woude; Adam Young; Keeranur Jayakumar; Bart J Mertens; René E M Toes; Désirée van der Heijde; Tom W J Huizinga; Annette H M van der Helm-van Mil Journal: Arthritis Rheum Date: 2009-08
Authors: Sanjay S Shete; Maria E Suarez-Almazor; Noha Abdel-Wahab; Adi Diab; Robert K Yu; Andrew Futreal; Lindsey A Criswell; Jean H Tayar; Ramona Dadu; Vickie Shannon Journal: Cancer Immunol Immunother Date: 2021-01-07 Impact factor: 6.968
Authors: Jia Luo; Victoria L Martucci; Alexander Gusev; Melinda C Aldrich; Matthew D Hellmann; Elad Ziv; Zoe Quandt; Stefan Groha; Megan H Murray; Christine M Lovly; Hira Rizvi; Jacklynn V Egger; Andrew J Plodkowski; Mohsen Abu-Akeel; Isabell Schulze; Taha Merghoub; Eduardo Cardenas; Scott Huntsman; Min Li; Donglei Hu; Matthew A Gubens Journal: Clin Cancer Res Date: 2021-07-08 Impact factor: 12.531
Authors: Ami A Shah; Laura C Cappelli; Tawnie J Braaten; Julie R Brahmer; Patrick M Forde; Dung Le; Evan J Lipson; Jarushka Naidoo; Megan Schollenberger; Lei Zheng; Clifton O Bingham Journal: Ann Rheum Dis Date: 2019-09-20 Impact factor: 19.103
Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751